ALP, alkaline phosphatase; AP, AP20187; Apoptosis resistance; BCL2, B cell lymphoma 2; Bcl-xL, B-cell lymphoma-extra large; Biliary epithelial cell; CCA, cholangiocarcinoma; CKI, cyclin-dependent kinase inhibitor; Cellular senescence; Cholestatic liver disease; Col.1A, collagen 1A; D, dasatinib; EVs, extracellular vesicles; FKBP-Casp8, FK506-binding-protein-caspase 8; IF, immunofluorescence; INK-ATTAC, p16Ink4a apoptosis through targeted activation of caspase; IR, irradiation; MCL1, myeloid cell leukemia 1; MCP-1, monocyte chemoattractant protein-1; MMP, matrix metalloproteinase; NHC, normal human cholangiocyte; PSC, primary sclerosing cholangitis; Primary sclerosing cholangitis; Q, quercetin; RT, reverse transcription; SA-ß-gal, senescence-associated ß-gal; SASP, senescence-associated secretory phenotype; Senescence-associated secretory phenotype; Senolytics; TNF, tumour necrosis factor; WT, wild-type; mdr2, multidrug-resistance 2; qPCR, quantitative PCR; α-SMA, α-smooth muscle actin; ß-Gal, ß-galactosidase